Ann: Noxopharm Announces Novel mRNA Vaccine Enhancer, page-8

Information on the target market size is useful information for investors.

But so is having an idea of development pathway. Are we expecting a phase 1 clinical trial in the next 1-2 years? Do we look for a development partner, or simply a supply agreement with an mRNA vaccine company for trials?

Or are they getting it ready to license as a pre-clinical asset? What is there left to do? How long will that take?

Communication is severely lacking with Noxopharm. Many other biotechs have outlined upcomming milestones with or without expected timeline.